Initiator Pharma Dirección

Dirección controles de criterios 2/4

El CEO de Initiator Pharma's es Claus Olesen, nombrado en May 2016, tiene una permanencia de 7.92 años. posee directamente un 2.03% de las acciones de la empresa, con un valor de SEK9.59M. La antigüedad media del equipo directivo y de la junta directiva es de 8.1 años y 5.5 años, respectivamente.

Información clave

Claus Olesen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	8yrs
Participación del CEO	2.0%
Permanencia media de la dirección	8.2yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Claus Olesen (49 yo)

8yrs

Permanencia

Dr. Claus Elsborg Olesen is Chief Executive Officer at Stipe Therapeutics. He serves Chief Executive Officer at Initiator Pharma A/S since May 02, 2016 and serves as its Director since September 19, 2016 a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Claus Olesen	Co-Founder	8yrs	sin datos	2.03% DKK 10.0m
Dan Peters	Co-Founder & CTO	8.3yrs	sin datos	sin datos
Ulf Simonsen	Co-Founder	no data	sin datos	1.17% DKK 5.8m
Mikael Thomsen	Co-Founder & Chief Development Officer	no data	sin datos	1.34% DKK 6.6m
Torgeir Vaage	Chief Financial Officer	8.3yrs	sin datos	sin datos
Allan Wehnert	Senior Vice President of Clinical and R&D Strategy & Portfolio Management	3.4yrs	sin datos	sin datos
Susanne Thomsen	Head of Clin Ops	no data	sin datos	sin datos
Rene Egebro	Head of CMC	no data	sin datos	sin datos

8.2yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de INIT es experimentado (8.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Claus Olesen	Co-Founder	7.7yrs	sin datos	2.03% DKK 10.0m
Gunnar Magnus Severus Persson	Chairman of the Board of Directors	7.7yrs	sin datos	0.49% DKK 2.4m
Henrik Moltke	Director	7.7yrs	sin datos	0.24% DKK 1.2m
Irwin Goldstein	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos
Gunilla Ekstrom	Independent Director	1.6yrs	sin datos	0.013% DKK 65.1k
Annette Colin	Director	3.3yrs	sin datos	0.65% DKK 3.2m
Peter Holm	Director	7.7yrs	sin datos	sin datos
Sue Goldstein	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos

5.5yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de INIT se considera experimentada (5.5 años de antigüedad promedio).

Initiator Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

No independent directors

No independent directors

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Announces Management Changes

Recent updates

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

New minor risk - Shareholder dilution

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction

New minor risk - Financial position

Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial

Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine (IP2015)

Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Forecast breakeven date pushed back to 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations

No independent directors

Initiator Pharma A/S Provides an Update on Its Clinical Programs

Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study

Initiator Pharma A/S has completed a Follow-on Equity Offering in the amount of SEK 2.499998 million.

Initiator Pharma A/S Reports Positive Efficacy Data Outcome of the Iptn2021 Program Phase I Study to Assess Pain-Reducing Effects

No independent directors

Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB

Initiator Pharma A/S Signs Option Agreement for Late-Stage Drug Candidate

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Initiates Dosing in the IPTN2021 Program Phase I Study to Assess Pain Reducing Effects

Initiator Pharma A/S Announces an Update on its Clinical Programs

Initiator Pharma A/S Receives CTA Approval for Iptn2021 Program Phase I Study to Assess Pain Reducing Effects

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Initiator Pharma Includes the First Patient in Phase 2B Study with Iped2015 in Erectile Dysfunction Patients

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Initiator Pharma Receives Approval for Phase 2a Study with IP2018

Forecast to breakeven in 2023

Initiator Pharma A/S Files its Clinical Trial Application for its Planned Phase II Study in Erectile Dysfunction Patients with IPED2015

New 90-day high: kr5.58

New 90-day low: kr4.18

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Initiator Pharma A/S Announces Management Changes

Initiator Pharma A/S announces First patient dosed in Phase 2a trial with IP2018

Initiator Pharma A/S announced that it expects to receive SEK 23 million in funding from MAC Clinical Research Ltd

Initiator Pharma Secures Funding for IPED2015 clinical Phase 2b study

New 90-day low: kr4.69

New 90-day low: kr4.99

Initiator Pharma A/S has completed a Composite Units Offering.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad